A specific inhibitor of PfCDPK4 blocks malaria transmission: chemical-genetic validation.
about
Development of potent and selective Plasmodium falciparum calcium-dependent protein kinase 4 (PfCDPK4) inhibitors that block the transmission of malaria to mosquitoesNeospora caninum calcium-dependent protein kinase 1 is an effective drug target for neosporosis therapyThe development of malaria parasites in the mosquito midgutMultiple short windows of calcium-dependent protein kinase 4 activity coordinate distinct cell cycle events during Plasmodium gametogenesis.Bumped kinase inhibitor 1294 treats established Toxoplasma gondii infection.Theileria equi isolates vary in susceptibility to imidocarb dipropionate but demonstrate uniform in vitro susceptibility to a bumped kinase inhibitorThe gatekeeper residue and beyond: homologous calcium-dependent protein kinases as drug development targets for veterinarian Apicomplexa parasites.A single mutation in the gatekeeper residue in TgMAPKL-1 restores the inhibitory effect of a bumped kinase inhibitor on the cell cycle.In Vitro and In Vivo Effects of the Bumped Kinase Inhibitor 1294 in the Related Cyst-Forming Apicomplexans Toxoplasma gondii and Neospora caninumSelective inhibition of Sarcocystis neurona calcium-dependent protein kinase 1 for equine protozoal myeloencephalitis therapy.Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis.Review of Experimental Compounds Demonstrating Anti-Toxoplasma Activity.Reduced Activity of Mutant Calcium-Dependent Protein Kinase 1 Is Compensated in Plasmodium falciparum through the Action of Protein Kinase G.Designing selective inhibitors for calcium-dependent protein kinases in apicomplexans.Calcium signalling in malaria parasites.5-Aminopyrazole-4-carboxamide analogues are selective inhibitors of Plasmodium falciparum microgametocyte exflagellation and potential malaria transmission blocking agents.Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy.Extended-spectrum antiprotozoal bumped kinase inhibitors: A review.Active Compounds Against Anopheles minimus Carboxypeptidase B for Malaria Transmission-Blocking Strategy.Advances in bumped kinase inhibitors for human and animal therapy for cryptosporidiosis.ALBA4 modulates its stage-specific interactions and specific mRNA fates during Plasmodium yoelii growth and transmission.Invasion of hepatocytes by Plasmodium sporozoites requires cGMP-dependent protein kinase and calcium dependent protein kinase 4.Plasmodium falciparum Calcium-Dependent Protein Kinase 2 Is Critical for Male Gametocyte Exflagellation but Not Essential for Asexual Proliferation.Kinobead and Single-Shot LC-MS Profiling Identifies Selective PKD Inhibitors.In vitro growth inhibition of Theileria equi by bumped kinase inhibitors.Safety and efficacy of the bumped kinase inhibitor BKI-1553 in pregnant sheep experimentally infected with Neospora caninum tachyzoites.Plasmodial Kinase Inhibitors: License to Cure?Epistasis studies reveal redundancy among calcium-dependent protein kinases in motility and invasion of malaria parasites
P2860
Q27681748-A6EAA26C-4DB3-40C9-9396-9A71BB130FFCQ27682650-A6C0F65D-7E10-4706-B876-AA3BEC76973EQ28074078-81A81E2D-81C3-4ED8-A137-3F12234FF8C0Q33758322-8C48FBDB-B670-4A85-B7AF-B4CF1633B6A3Q33797884-3216AC72-1C1B-4B02-85A9-56073C2B97F2Q35030076-C671E936-DF22-4D8D-9CD4-050C05109DD4Q35187684-C0A6DD25-D307-4040-AA68-64DE3810A707Q35547947-0AF8FF8C-1016-42EE-98E4-B739BF5BDB40Q36076061-3510DF03-FA54-41DF-BCBE-E95F20AD1EB9Q36160956-D79C7C0C-3A97-4514-BF44-C7DD811BDAB9Q37401607-85FDBA56-4C37-4891-AF33-063745BC4785Q37428599-CC61C12F-85D8-4BB7-B518-5005BFE11434Q37481769-526F9AA9-34C6-48CC-A7D2-50E338D46B43Q38443813-B710AB5E-6CEB-4BD7-8B3D-C74275F35A14Q38691315-41B2C94E-FA76-4355-B402-AEEE2261A306Q38736811-83F6A9C4-D469-4523-96C6-04F3FA6EC681Q38886453-7CAEB396-DB68-41C9-BADD-3B7DA883078AQ39075089-33D68DCE-E046-4638-9885-035E4CA9C1E3Q39263004-589EA19D-4551-4D0B-AA4E-C0B7B7EDAFACQ40050616-4F1C75E0-F399-47D8-8962-4219108368B7Q40101945-DADFD4C1-45C7-4981-ACB3-47AD9828D190Q40610678-30C28959-FA07-4461-928C-A335A79B697EQ42379912-E5F79208-EBCF-4A07-8E84-9F30DA2141BAQ48336339-9A6B1209-237C-479F-8437-96AD5C5A00DFQ50093358-E8901268-3E70-447F-82FC-DF5777B03B92Q51744820-D39D7B0F-06C3-46AD-AF97-391AC8E518DBQ54978870-3CF7A366-27F9-444F-A5A3-6FD600807864Q57471962-001E3A58-6263-48D4-8193-FB8980BEC194
P2860
A specific inhibitor of PfCDPK4 blocks malaria transmission: chemical-genetic validation.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A specific inhibitor of PfCDPK4 blocks malaria transmission: chemical-genetic validation.
@en
A specific inhibitor of PfCDPK4 blocks malaria transmission: chemical-genetic validation.
@nl
type
label
A specific inhibitor of PfCDPK4 blocks malaria transmission: chemical-genetic validation.
@en
A specific inhibitor of PfCDPK4 blocks malaria transmission: chemical-genetic validation.
@nl
prefLabel
A specific inhibitor of PfCDPK4 blocks malaria transmission: chemical-genetic validation.
@en
A specific inhibitor of PfCDPK4 blocks malaria transmission: chemical-genetic validation.
@nl
P2093
P2860
P50
P921
P356
P1476
A specific inhibitor of PfCDPK4 blocks malaria transmission: chemical-genetic validation
@en
P2093
Anna M W Fox
Christophe L M J Verlinde
Dale J Kempf
Erkang Fan
Justin D Lutz
Kasey L Rivas
Kayode K Ojo
Kenneth M Comess
Laura M Kim
Mark Kennedy
P2860
P304
P356
10.1093/INFDIS/JIT522
P407
P577
2013-10-10T00:00:00Z